IF 4.7 3区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Jorge Vela-Ojeda , Aline Ramirez-Alvarado , Ana Sofia Sanchez-Rodriguez , Jaime Garcia-Chavez , Laura Arcelia Montiel-Cervantes
{"title":"Extraosseous Plasmacytoma Confers Poor Outcomes in Primary Plasma Cell Leukemia","authors":"Jorge Vela-Ojeda ,&nbsp;Aline Ramirez-Alvarado ,&nbsp;Ana Sofia Sanchez-Rodriguez ,&nbsp;Jaime Garcia-Chavez ,&nbsp;Laura Arcelia Montiel-Cervantes","doi":"10.1016/j.arcmed.2025.103207","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Primary plasma cell leukemia (PPCL) is one of the most aggressive diseases in oncohematology. Due to its low incidence, there is no established standard treatment, and it is considered an incurable disease.</div></div><div><h3>Aims</h3><div>This study presents our experience and outcomes of 92 cases of PPCL between January 2011 and December 2020.</div></div><div><h3>Methods</h3><div>Fat pad biopsy was positive for Congo red in six (35 %) of 17 patients, solitary extraosseous plasmacytoma was observed in 30 (32.5 %), and bone marrow fibrosis was identified in 81 (88 %) patients.</div></div><div><h3>Results</h3><div>While most patients (69.5 %) received conventional chemotherapy combinations, 30.5 % underwent proteasome inhibitor-based treatment and/or autologous stem cell transplantation (auto-SCT). In this series, we report that the presence of extraosseous plasmacytoma, treatment failure, and therapy with classic chemotherapy agents were independent covariates associated with poor survival.</div></div><div><h3>Conclusions</h3><div>In PPCL, extraosseous plasmacytoma, treatment failure, and treatment with conventional chemotherapy were associated with poor outcomes.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"56 5","pages":"Article 103207"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S018844092500027X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景原发性浆细胞白血病(PPCL)是肿瘤血液学中最具侵袭性的疾病之一。本研究介绍了我们在 2011 年 1 月至 2020 年 12 月期间对 92 例 PPCL 患者的治疗经验和结果。方法 17 例患者中有 6 例(35%)的脂肪垫活检呈刚果红阳性,30 例(32.5%)患者观察到单发骨外浆细胞瘤,81 例(88%)患者发现骨髓纤维化。结果大多数患者(69.5%)接受了常规化疗,30.5%接受了蛋白酶体抑制剂治疗和/或自体干细胞移植(auto-SCT)。在该系列研究中,我们发现骨外浆细胞瘤的存在、治疗失败和传统化疗药物治疗是与不良生存率相关的独立协变量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Extraosseous Plasmacytoma Confers Poor Outcomes in Primary Plasma Cell Leukemia

Background

Primary plasma cell leukemia (PPCL) is one of the most aggressive diseases in oncohematology. Due to its low incidence, there is no established standard treatment, and it is considered an incurable disease.

Aims

This study presents our experience and outcomes of 92 cases of PPCL between January 2011 and December 2020.

Methods

Fat pad biopsy was positive for Congo red in six (35 %) of 17 patients, solitary extraosseous plasmacytoma was observed in 30 (32.5 %), and bone marrow fibrosis was identified in 81 (88 %) patients.

Results

While most patients (69.5 %) received conventional chemotherapy combinations, 30.5 % underwent proteasome inhibitor-based treatment and/or autologous stem cell transplantation (auto-SCT). In this series, we report that the presence of extraosseous plasmacytoma, treatment failure, and therapy with classic chemotherapy agents were independent covariates associated with poor survival.

Conclusions

In PPCL, extraosseous plasmacytoma, treatment failure, and treatment with conventional chemotherapy were associated with poor outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Medical Research
Archives of Medical Research 医学-医学:研究与实验
CiteScore
12.50
自引率
0.00%
发文量
84
审稿时长
28 days
期刊介绍: Archives of Medical Research serves as a platform for publishing original peer-reviewed medical research, aiming to bridge gaps created by medical specialization. The journal covers three main categories - biomedical, clinical, and epidemiological contributions, along with review articles and preliminary communications. With an international scope, it presents the study of diseases from diverse perspectives, offering the medical community original investigations ranging from molecular biology to clinical epidemiology in a single publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信